All In Biotech

Drug Trial Radar · NCT07365826

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,390

Actual

Start

Jan 12, 2026

Primary completion

Oct 21, 2026

Study completion Oct 21, 2026

Sponsor

Lead sponsor
Vaxcyte, Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.

Conditions

  • Pneumococcal Disease

Interventions

  • 31-valent pneumococcal conjugate vaccineBiological

    0.5 mL of VAX-31 will be administered into the deltoid muscle

  • Seasonal Influenza Vaccine (SIV) (Flublok)Biological

    0.5 mL of SIV into the deltoid muscle

  • PlaceboBiological

    0.5mL of placebo (normal saline) into the deltoid muscle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For each of the 32 serotypes (the 31 serotypes included in VAX-31, and serotype 20B), the ratio (co-administration group to sequential administration group) of opsonophagocytic activity (OPA) geometric mean titers (GMT) in evaluable participantsTime frame: 1 Month after VAX-31 vaccination
  2. For each of the strains in SIV, the ratio (co-administration group to sequential administration group) of hemagglutination inhibition (HAI) GMT in evaluable participantsTime frame: 1 Month after SIV administration
  3. Percentage of participants reporting solicited local adverse events (AE) within 7 days after Day 1 and Month 1 vaccination (redness, swelling, and pain at injection site) in each groupTime frame: 7 days after each vaccination
  4. Percentage of participants reporting solicited systemic AE within 7 days after Day 1 and Month 1 vaccination (fever, headache, fatigue, muscle pain, and joint pain) in each groupTime frame: 7 days after each vaccination
  5. Percentage of participants reporting unsolicited AE within 1 month after Day 1 and Month 1 vaccination in each groupTime frame: 7 days after each vaccination
  6. Percentage of participants reporting NOCI, MAAE, and SAE within 6 months after last vaccination in each groupTime frame: 6 Months after last vaccination

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Hope Research Institute

    Phoenix, Arizona

  • Tekton Research at Fort Collins

    Fort Collins, Colorado

  • University Clinical Research - Deland

    DeLand, Florida

  • CenExel Research Centers of America

    Hollywood, Florida

  • Health Awareness

    Jupiter, Florida

  • Accel Research Sites - Lakeland

    Lakeland, Florida

  • Accel Research Sites - Largo

    Largo, Florida

  • Precision Clinical Research

    Sunrise, Florida

  • Velocity Valparaiso

    Valparaiso, Indiana

  • Johnson County ClinTrials

    Lenexa, Kansas

  • AMR Lexington

    Lexington, Kentucky

  • DM Clinical Research - Detroit

    Detroit, Michigan

  • Velocity Omaha

    Omaha, Nebraska

  • Rochester Clinical Research

    Rochester, New York

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • DelRicht Research - Hendersonville

    Hendersonville, Tennessee

  • AMR Knxoville

    Knoxville, Tennessee

  • Tekton Research at Austin

    Austin, Texas

  • REX Clinical Trials

    Beaumont, Texas

  • Epic Medical Research

    DeSoto, Texas

  • CenExel JBR Clinical Research

    Salt Lake City, Utah

  • Charlottesville Medical Research Center

    Charlottesville, Virginia

  • Health Research of Hampton Roads, Inc.

    Newport News, Virginia

  • Clinical Research Partners, LLC.

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.